AZN · Pharma and healthcare · one day
AstraZeneca (AZN): news on Saturday 21 November 2026
News from the 24 hours to Saturday morning, 21 November 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mostly about regulatory progress, with a priority review in the US for its gastric cancer drug and a positive EU opinion for Baxfendy, alongside a new SAP partnership. Some caution came from a weak short-term share price trend and mentions of board changes and AI worries.
What drove it
- FDA priority review
- Baxfendy EU opinion
- SAP partnership
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Sun 15 Nov | +7.5 | 9 |
| Mon 16 Nov | +4.5 | 6 |
| Tue 17 Nov | +9.7 | 45 |
| Wed 18 Nov | +7.0 | 29 |
| Thu 19 Nov | +5.5 | 23 |
| Fri 20 Nov | +8.0 | 19 |
| Sat 21 Nov | +7.0 | 12 |
7 stories · 12 headlines · strongest first
Pharma and healthcare on 21 NovemberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Sone-Ve, AstraZeneca's gastric cancer drug, receives priority review from the FDA +9.53 headlines today · 16 in all, since 20 November · Several outlets report FDA priority review for AstraZeneca's gastric cancer drug. | ||
| +10.0 | Regulator fast-tracks review of its gastric cancer drug application. | |
| +10.0 | US regulator gives accelerated review to its gastric cancer filing. | |
| +9.2 | Priority review granted by US regulator for its cancer drug. | |
| AstraZeneca share price moves −0.23 headlines today · 7 in all, since 19 November · Pieces discuss share support levels, pipeline strength and delivery. | ||
| +9.7 | Described as ahead of European peers on growth and pipeline. | |
| −5.0 | Technical analysis notes sellers dominating near a support level. | |
| +1.7 | Opinion piece on whether product delivery changes investor perception. | |
| AstraZeneca signs cloud ERP deal with SAP +2.52 headlines today · 9 in all, since 15 November · Outlets report AstraZeneca's cloud partnership with SAP. | ||
| +5.0 | Software firm partnership extends AstraZeneca's technology tie-up. | |
| −1.7 | Cloud contract win offset by board changes and AI worries. | |
| Positive EU opinion for AstraZeneca's Baxfendy +9.21 headline today · A piece covers a positive EU opinion for Baxfendy. | ||
| +9.2 | Favourable European regulatory opinion for its product Baxfendy. | |
| Saudi Heart Association and AstraZeneca sign MoU +5.01 headline today · The Saudi Heart Association and AstraZeneca signed an MoU on cardiac research and training. | ||
| +5.0 | Cooperation agreement on cardiac research and training in Saudi Arabia. | |
| AstraZeneca appoints Sandhya Sapra as its lung tumour lead +0.81 headline today · Sandhya Sapra joined AstraZeneca for oncology outcomes research. | ||
| +0.8 | Routine senior hire in oncology research team. | |
| AstraZeneca discusses patient association networking +0.81 headline today · An AstraZeneca executive spoke about working with patient associations. | ||
| +0.8 | Executive comments on engaging patient groups; neutral. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated AstraZeneca: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.